Security key
59102M104
- Security type / class
- Equity / COM
- Total 13F shares
- 12,188,453
- Total 13F value
- $49,568,061
- Share change
- -1,155,964
- SEC-reported price per share
- $4.08
- Number of holders
- 54
- Value change
- -$9,507,864
- Number of buys
- 28
- Number of sells
- 24
Report period
Q2 2024
Institutions
54
Top holders
10
MGX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Metagenomi Therapeutics, Inc. SEC filings
Metagenomi Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 59102M104
Recent filing periods:
Ownership snapshot
Top reported holders of MGX - Metagenomi Therapeutics, Inc. - COM (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Novo Holdings A/S
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
0/15
Latest evidence
01 Apr 2024
13F
3/4/5
Highest disclosed value: $18,403,578
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
RA CAPITAL MANAGEMENT, L.P. has the largest disclosed position value at $18.4M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.
Disclosed position value
Top 5
Novo Holdings A/S
$18.35M
BAYER HEALTHCARE LLC
$11.67M
RA CAPITAL MANAGEMENT, L.P.
$18.4M
FARALLON CAPITAL MANAGEMENT, L.L.C.
$14.17M
PFM Health Sciences, LP
$13.37M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Novo Holdings A/S |
13F
3/4/5
Company · 10%+ Owner
|
—
class O/S missing
|
$18,348,296
1,739,175 shares
|
— | 31 Mar 2024 |
| BAYER HEALTHCARE LLC |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$11,666,871
4,050,997 shares
|
— | 13 Feb 2024 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
—
class O/S missing
|
$18,403,578
1,744,415 shares
|
— | 31 Mar 2024 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. |
13F
Company
|
—
class O/S missing
|
$14,170,771
1,343,201 shares
|
— | 31 Mar 2024 |
| PFM Health Sciences, LP |
13F
Company
|
—
class O/S missing
|
$13,366,871
1,267,002 shares
|
— | 31 Mar 2024 |
| HHLR ADVISORS, LTD. |
13F
Company
|
—
class O/S missing
|
$8,205,452
777,768 shares
|
— | 31 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
54
Shares
12,188,453
Rows available
54
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2024 vs Q1 2026 Across Filers
Q1 2026 holders
47
Q2 2024 holders
54
Holder diff
7
| Investor | Q1 2026 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend